JOHN OSTH — President and CEO of Celula, Inc.
John Osth, President and CEO of Celula, Inc., joined the company May 1, 2008.
Prior to joining Celula, Mr. Osth was COO of HematoLogics, Inc. in Seattle, WA. HematoLogics provides advanced diagnostics lab services to Pathologists and Oncologists. Testing service technologies included flow cytometry, cell sorting, Polymerase Chain Reaction (PCR), Fluorescence In-situ Hybridization (FISH) and cytogenetics. Mr. Osth was responsible for all business operations including financial, sales and marketing.
Prior to joining HematoLogics, Inc., Mr. Osth was founder, Chairman and CEO of QuantumCor, Inc., a company developing a percutaneous method for repairing mitral valves. In addition to his role at Celula, Mr. Osth remains Chairman of QuantumCor, Inc. Previous to QuantumCor, Mr. Osth was employed by Baxter Healthcare where he was President of the Immunotherpy Division and headed Baxter’s European Research and Development Group based in Belgium.
Mr. Osth received his MBA from The Executive Program at the University of Chicago in 1978. He also holds an MS in Engineering from the University of Illinois, Champaign, IL, and a BS in Engineering from the U.S. Naval Academy, Annapolis, MD.
ANDY KATZ, PH.D. - Vice President and Chief Business Officer
Andy Katz, Ph.D. Vice President & Chief Business Officer is a co-founder of Celula.
Prior to joining Celula, Dr. Katz was Senior Director, Corporate Development & Strategic Marketing at Genoptix, Inc., a provider of distinctive diagnostic services for hematopathology. In his role he provided product and sales force management, including securing contracts for services supporting FDA-regulated clinical trials to pharma clients. Dr. Katz performed market research to establish performance specifications for the engineering team at Genoptix that ultimately lead to Celula’s cell sorting instrument.
Prior to joining Genoptix, he was a consultant with McKinsey & Company in Los Angeles where he advised senior management at major companies to achieve superior and sustained growth & performance improvements in competitive strategy, operations, and organization.
Dr. Katz completed his Ph.D. in 1998 at the University of California, San Diego. His research at UCSD focused on electronic & optical properties of superconductors for development of manufacturable superconducting devices for ultra high-speed electronics and fabrication of magnetic sensors for the hard drive data storage industry. He has published 20 articles in scientific journals and has been issued two patents in nanotechnology. Dr. Katz holds a B.S. in Applied Physics and a B.A. in Humanities (magna cum laude) from Columbia University.
HAICHUAN ZHANG, PH.D. - Vice President, Research & Development
Haichuan Zhang, Ph.D. Vice President of Engineering is a co-founder of Celula.
Prior to joining Celula, Dr. Zhang was Principal Electronic Engineer and a project manager at Genoptix Inc. from 2001 to 2005, where he led the system design and technical project management for several laser based instruments including the development of a proprietary microfluidic sorter.
Prior to joining Genoptix, Dr. Zhang was a chief engineer and technical staff at Call/Recall Inc. from 1997 to 2001, where he has conducted research on two-photon absorption based optical 3-D memory funded by the Defense Advanced Research Projects Agency (DARPA) and the Air Force Research Laboratory (AFRL).
Dr. Zhang has more than 10 years of experience in complex system design, integration and project management. He also has more than 20 publications and 6 patents.
Dr. Zhang received a Ph.D. in Precision Instrument & Machinery from Tsinghua University, China 1997. He also received two B.S. degrees in Precision Instrument and Electronics & Computer Technology from Tsinghua University.
KURT KRUMMEL, PH.D. - Associate Director, Biology
Kurt Krummel, Ph.D. joined Celula in 2006 and is currently the Manager of Biological Applications.
Prior to joining Celula, he was a post-doctoral researcher at The Salk Institute (La Jolla, CA). He led a technical team on an NIH funded scientific study of the tumor suppressor gene, p53. This work in mouse models served as a paradigm for understanding transcription factor signaling networks in cancer and resulted in several high profile publications in prestigious peer-reviewed journals. He also routinely reviewed and edited manuscripts for peer-reviewed journal and collaborated with Dr. Geoffrey Wahl in grant writing for postdoctoral and R01 funds.
Dr. Krummel received his Bachelor's degree in Biology from The University of Wisconsin (Whitewater, WI), and in 2001, he received his Ph.D. in Molecular Biology from The Mayo Clinic (Rochester, MN). While at Mayo, he characterized and compared novel homologous regions of the human and mouse genomes that are prone to breakage and rearrangement in a variety of cancer types to understand the molecular basis for the instability implicated in tumorigenesis.
